Pfizer (NYSE:PFE) Releases FY 2025 Earnings Guidance

Pfizer (NYSE:PFE) updated its FY 2025 earnings guidance on Tuesday. The company provided earnings per share guidance of 2.800-3.000 for the period, compared to the consensus earnings per share estimate of 2.880. The company issued revenue guidance of $61.0 billion-$64.0 billion, compared to the consensus revenue estimate of $63.3 billion.

Analyst Upgrades and Downgrades

PFE has been the topic of a number of research reports. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 target price on shares of Pfizer in a report on Wednesday, October 23rd. Wolfe Research began coverage on shares of Pfizer in a report on Friday, November 15th. They issued an “underperform” rating and a $25.00 price objective for the company. Sanford C. Bernstein started coverage on Pfizer in a research note on Thursday, October 17th. They issued a “market perform” rating and a $32.00 price target for the company. Evercore ISI raised Pfizer to a “strong-buy” rating in a research report on Wednesday, October 30th. Finally, Citigroup assumed coverage on Pfizer in a report on Friday, October 25th. They issued a “neutral” rating and a $30.00 price objective for the company. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating, five have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, Pfizer has a consensus rating of “Hold” and a consensus target price of $32.15.

Pfizer Price Performance

PFE stock opened at $25.26 on Tuesday. The firm has a market cap of $143.15 billion, a price-to-earnings ratio of 34.14, a PEG ratio of 0.63 and a beta of 0.65. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The company’s fifty day simple moving average is $27.09 and its 200 day simple moving average is $28.25. Pfizer has a 12-month low of $24.48 and a 12-month high of $31.54.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.42. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The business had revenue of $17.70 billion for the quarter, compared to analyst estimates of $14.92 billion. During the same quarter in the prior year, the company earned ($0.17) earnings per share. The company’s quarterly revenue was up 31.2% on a year-over-year basis. On average, analysts expect that Pfizer will post 2.95 earnings per share for the current year.

Pfizer Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be paid a $0.43 dividend. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date of this dividend is Friday, January 24th. This represents a $1.72 annualized dividend and a dividend yield of 6.81%. Pfizer’s dividend payout ratio is presently 227.03%.

Insider Activity at Pfizer

In other Pfizer news, Director Scott Gottlieb acquired 1,000 shares of the company’s stock in a transaction on Wednesday, October 30th. The shares were acquired at an average cost of $28.24 per share, with a total value of $28,240.00. Following the completion of the acquisition, the director now directly owns 10,000 shares in the company, valued at $282,400. This trade represents a 11.11 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.06% of the stock is currently owned by company insiders.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.